Placebo News and Research

RSS

IGF-1 not beneficial for amyotrophic lateral sclerosis

A growth hormone that had shown some promise for treating people with amyotrophic lateral sclerosis (ALS) showed no benefit in a new study published in the November 25, 2008, issue of Neurology , the medical journal of the American Academy of Neurology.

24 Nov 2008

Valdoxan - a melatonergic antidepressant - receives positive European opinion for major depressive disorder

The first melatonergic antidepressant - Valdoxan/Thymanax (agomelatine) - has received a positive opinion from the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) for its use in the treatment of adult patients with major depressive disorder (MDD).

21 Nov 2008

Nplate receives positive opinion for marketing authorisation in Europe

Amgen has announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for Nplate (romiplostim) in the European Union (EU).

21 Nov 2008

Long-term use of a macrolide antibiotic reduce COPD exacerbations, raise questions

Long-term use of a macrolide antibiotic may reduce the frequency of exacerbations in patients with moderate to severe chronic obstructive pulmonary disease (COPD) by as much as 35 percent, according to a London-based study.

21 Nov 2008

FDA approves tapentadol immediate-release tablets for pain in adults

Millions of Americans with moderate to severe acute pain and their health-care providers will soon have a new treatment option.

21 Nov 2008

FDA accepts filing and grants priority review for DX-88 for hereditary angioedema

Dyax Corp. has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's Biologics License Application (BLA) for DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) and has designated the application for Priority Review.

21 Nov 2008

Gefitinib just as effective as chemotherapy for lung cancer

Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center.

20 Nov 2008

FDA approves GSK's Promacta (Eltrombopag)

GlaxoSmithKline has announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

20 Nov 2008

FDA approves Banzel (rufinamide) for Lennox-Gastaut syndrome

The U.S. Food and Drug Administration has approved a new drug, Banzel (rufinamide), for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome.

20 Nov 2008

XTL Biopharmaceuticals announces results from Bicifadine in diabetic neuropathic pain trial

XTL Biopharmaceuticals Ltd. has announced the top-line results from the Bicifadine Phase 2b clinical trial for the treatment of diabetic neuropathic pain.

19 Nov 2008

Metabolex announces positive results from phase 2 trial of MBX-8025

The Phase 2 study was a randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of MBX-8025, both alone and in combination with atorvastatin (marketed as Lipitor(R)), over an 8-week treatment period.

19 Nov 2008

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

19 Nov 2008

Ginkgo biloba does nothing for dementia, Alzheimer's

One of the most widely used herbal supplements for improving memory and cognition has no impact on the development of dementia or Alzheimer's disease, according to new results from a $30 million, multi-center study.

18 Nov 2008

Accera to launch Axona, medical food product for Alzheimer's in 2009

Accera, Inc. will launch Axona in the United States for Alzheimer's disease (AD) in the first quarter of 2009.

18 Nov 2008

NCI sponsors Canadian cold/flu remedy trial in leukemia patients

Cancer patients, with their weakened immune systems, are particularly vulnerable when the cold and flu season hits. The National Cancer Institute (NCI), part of the National Institutes of Health and the world's most prestigious cancer research body, is sponsoring a landmark trial to evaluate if a unique Canadian cold remedy - ginseng extract COLD-FX - can help.

18 Nov 2008

Ginkgo's benefits for cognitive decline treatment supported by scientific research

A vast body of research supports numerous health benefits for ginkgo extracts, particularly for treating various symptoms and conditions associated with declining cognitive performance and poor circulation, says the American Botanical Council, an independent nonprofit research and education organization.

18 Nov 2008